KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Consolidated Net Income (2016 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed Consolidated Net Income for 18 consecutive years, with $727.2 million as the latest value for Q1 2026.

  • For Q1 2026, Consolidated Net Income fell 10.08% year-over-year to $727.2 million; the TTM value through Mar 2026 reached $4.4 billion, down 1.69%, while the annual FY2025 figure was $4.5 billion, 2.09% up from the prior year.
  • Consolidated Net Income hit $727.2 million in Q1 2026 for Regeneron Pharmaceuticals, down from $844.6 million in the prior quarter.
  • Across five years, Consolidated Net Income topped out at $1.5 billion in Q3 2025 and bottomed at $722.0 million in Q1 2024.
  • Average Consolidated Net Income over 5 years is $1.1 billion, with a median of $973.5 million recorded in 2022.
  • Year-over-year, Consolidated Net Income tumbled 72.5% in 2022 and then skyrocketed 47.9% in 2024.
  • Regeneron Pharmaceuticals' Consolidated Net Income stood at $1.2 billion in 2022, then decreased by 3.13% to $1.2 billion in 2023, then fell by 20.86% to $917.7 million in 2024, then decreased by 7.97% to $844.6 million in 2025, then decreased by 13.9% to $727.2 million in 2026.
  • According to Business Quant data, Consolidated Net Income over the past three periods came in at $727.2 million, $844.6 million, and $1.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.